1. |
Siegel RL, Giaquinto AN, Jemal A. Cancer statistics, 2024. CA Cancer J Clin, 2024, 74(1): 12-49.
|
2. |
Cassinotto C, Nogue E, Morell M, et al. Changing trends in hepatocellular carcinoma management: Results from a nationwide database in the last decade. Eur J Cancer, 2021, 146: 48-55.
|
3. |
郝运, 李川, 文天夫, 等. 全球及中国的肝癌流行病学特征: 基于《2022全球癌症统计报告》解读. 中国普外基础与临床杂志, 2024, 31(7): 781-789.
|
4. |
姚一菲, 孙可欣, 郑荣寿. 《2022全球癌症统计报告》解读: 中国与全球对比. 中国普外基础与临床杂志, 2024, 31(7): 769-780.
|
5. |
Rumgay H, Arnold M, Ferlay J, et al. Global burden of primary liver cancer in 2020 and predictions to 2040. J Hepatol, 2022, 77(6): 1598-1606.
|
6. |
中华人民共和国国家卫生健康委员会医政司原发性肝癌诊疗指南(2024年版). 中国普通外科杂志, 2024, 33(4): 475-530.
|
7. |
Edge SE, Byrd DR, Carducci M A, et al. AJCC cancer staging manual. 7th ed. New York, NY: Springer, 2009.
|
8. |
Devaki P, Wong RJ, Marupakula V, et al. Approximately one-half of patients with early-stage hepatocellular carcinoma meeting Milan criteria did not receive local tumor destructive or curative surgery in the post-MELD exception era. Cancer, 2014, 120(11): 1725-1732.
|
9. |
Reig M, Forner A, Rimola J, et al. BCLC strategy for prognosis prediction and treatment recommendation: The 2022 update. J Hepatol, 2022, 76(3): 681-693.
|
10. |
Anwanwan D, Singh SK, Singh S, et al. Challenges in liver cancer and possible treatment approaches. Biochim Biophys Acta Rev Cancer, 2020, 1873(1): 188314. doi: 10.1016/j.bbcan.2019.188314.
|
11. |
赖奉庭, 刘华强, 蔡永广. 卡瑞利珠单抗联合仑伐替尼或贝伐珠单抗治疗肝癌的疗效分析. 新医学, 2023, 54(6): 437-441.
|
12. |
Wen N, Cai Y, Li F, et al. The clinical management of hepatocellular carcinoma worldwide: A concise review and comparison of current guidelines: 2022 update. Biosci Trends, 2022, 16(1): 20-30.
|
13. |
Kalogeridi MA, Zygogianni A, Kyrgias G, et al. Role of radiotherapy in the management of hepatocellular carcinoma: A systematic review. World J Hepatol, 2015, 7(1): 101-112.
|
14. |
Booth CM, Tannock IF. Randomised controlled trials and population-based observational research: partners in the evolution of medical evidence. Br J Cancer, 2014, 110(3): 551-555.
|
15. |
Kim GA, Shim JH, Kim MJ, et al. Radiofrequency ablation as an alternative to hepatic resection for single small hepatocellular carcinomas. Br J Surg, 2016, 103(1): 126-135.
|
16. |
Bai XM, Cui M, Yang W, et al. The 10-year survival analysis of radiofrequency ablation for solitary hepatocellular carcinoma 5 cm or smaller: primary versus recurrent HCC. Radiology, 2021, 300(2): 458-469.
|
17. |
Wu S, Li Z, Yao C, et al. Progression of hepatocellular carcinoma after radiofrequency ablation: Current status of research. Front Oncol, 2022, 12: 1032746. doi: 10.3389/fonc.2022.1032746.
|
18. |
Maeda M, Saeki I, Sakaida I, et al. Complications after radiofrequency ablation for hepatocellular carcinoma: A multicenter study involving 9 411 Japanese patients. Liver Cancer, 2020, 9(1): 50-62.
|
19. |
Ng KKC, Chok KSH, Chan ACY, et al. Randomized clinical trial of hepatic resection versus radiofrequency ablation for early-stage hepatocellular carcinoma. Br J Surg, 2017, 104(13): 1775-1784.
|
20. |
Kimura T, Aikata H, Takahashi S, et al. Stereotactic body radiotherapy for patients with small hepatocellular carcinoma ineligible for resection or ablation therapies. Hepatol Res, 2015, 45(4): 378-386.
|
21. |
Bae SH, Chun SJ, Chung JH, et al. Stereotactic body radiation therapy for hepatocellular carcinoma: meta-analysis and International Stereotactic Radiosurgery Society practice guidelines. Int J Radiat Oncol Biol Phys, 2024, 118(2): 337-351.
|
22. |
Wahl DR, Stenmark MH, Tao Y, et al. Outcomes after stereotactic body radiotherapy or radiofrequency ablation for hepatocellular carcinoma. J Clin Oncol, 2016, 34(5): 452-459.
|
23. |
Kim N, Cheng J, Jung I, et al. Stereotactic body radiation therapy vs. radiofrequency ablation in Asian patients with hepatocellular carcinoma. J Hepatol, 2020, 73(1): 121-129.
|
24. |
Huertas A, Baumann AS, Saunier-Kubs F, et al. Stereotactic body radiation therapy as an ablative treatment for inoperable hepatocellular carcinoma. Radiother Oncol, 2015, 115(2): 211-216.
|
25. |
Lu Y, Lin B, Li M. The role of alpha-fetoprotein in the tumor microenvironment of hepatocellular carcinoma. Front Oncol, 2024, 14: 1363695. doi: 10.3389/fonc.2024.1363695.
|
26. |
江振辉, 胡晓川, 吴文明, 等. 肝癌术后预后列线图的建立和验证. 肝胆胰外科杂志, 2023, 35(11): 649-659.
|
27. |
Rajyaguru DJ, Borgert AJ, Smith AL, et al. Radiofrequency ablation versus stereotactic body radiotherapy for localized hepatocellular carcinoma in nonsurgically managed patients: Analysis of the National Cancer Database. J Clin Oncol, 2018, 36(6): 600-608.
|